Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 14;12:10163–10172. doi: 10.2147/CMAR.S270328

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Zhang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

MiR-186 inhibited SNHG7 to promote trastuzumab resistance in BC cells. (A) Effects of co-transfection of si-SNHG7+miR-186 inhibitor on the sensitivity of drug-resistant cells to trastuzumab. (B) Effects of co-transfection of si-SNHG7+miR-186 inhibitor on proliferation of drug-resistant cells. (C) Effects of co-transfection of si-SNHG7+miR-186 inhibitor on migration of drug-resistant cells. (D) Effects of co-transfection of si-SNHG7+miR-186 inhibitor on apoptosis of drug-resistant cells. (E) Effects of co-transfection of si-SNHG7+miR-186 inhibitor on EMT levels of drug-resistant cells. (F) DLR results. *** P<0.001.